The company, which originally started out in 1998 and was acquired by Pfizer Inc

In 2011, Clovis paid an undisclosed up-front fee to Pfizer Inc., of New York, plus potential milestones of $255 million, in exchange for the right to develop and commercialize the oral Poly(ADP-ribose) polymerase, or PARP, inhibitor, then in Phase I studies

Pearl reported Phase IIb results in 2011 that showed a statistically significant improvement in FEV1 of 47 percent over Foradil (formoterol, Novartis AG) and 49 percent over Spiriva (tiotroprium, Pfizer Inc./Boehringer Ingelheim GmbH) after one week of dosing (p < 0.0001 for both comparisons...Inc., Pfizer Inc., Novartis and AstraZeneca have products in that space

In 2011, Clovis paid an undisclosed up-front fee to Pfizer Inc., of New York, plus potential milestones of $255 million, in exchange for the right to develop and commercialize the oral Poly(ADP-ribose) polymerase, or PARP, inhibitor, then in Phase I studies

Ltd. (Tokyo) Tolvaptan A selective vasopressing receptor antagonist Autosomal dominant polycystic kidney disease FDA accepted an NDA 4/15/13 Pfizer Inc. (New York) Xeljanz Tofacitnib citrate Rheumatoid arthritis CHMP adopted a negative opinion 4/29/13 Sanofi Pasteur Ltd. (Lyon, France) Vaxigrip Quadrivalent formulation

Company (Location) Product Description Indication Status Date Pfizer Inc. (New York) Prevenar 13 Pneumococcal polysaccharide conjugate vaccine Infections Phase III data showed it met all primary and secondary objectives focused on immunogenicity, tolerability and safety in adults 18 to 49 4/30/13 Tetraphase Pharmaceuticals Inc. (Watertown, Mass.) Antibiotics Two next-generation antibiotic candidates Community-acquired multidrug-resistant infections Studies demonstrated efficacy 4/30/13 Trius

In the space of a few weeks that year the FDA approved Pfizer Inc.'s targeted therapy Xalkori (crizotinib) to treat certain patients with late-stage, non-small cell lung cancers (NSCLC) who express the abnormal anaplastic lymphoma kinase (ALK) gene

Company (Location) Product Description Indication Status Date AUTOIMMUNE Rigel Pharmaceuticals Inc. (South San Francisco) and AstraZeneca plc (London) Fostamatinib Oral spleen tyrosine kinase inhibitor Rheumatoid arthritis Missed the X-ray endpoint of modified Total Sharp score, but hit statistical significance in ACR20 scoring, although the Phase III still fell short of those achieved by Pfizer Inc.'s approved Xeljanz 4/8/13 CANCER Array BioPharma Inc. (Boulder, Colo.) ARRY-520 A selective KSP

In a footnote to its recent 10-Q filing, Pfizer Inc

Lumena licensed LUM001 from Pfizer Inc., of New York, where the compound was studied as a potential cholesterol-lowering agent

Bristol-Myers Squibb Co., of New York, and Pfizer Inc., also of New York, said results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, showing that the reductions in stroke or systemic embolism, number of major bleeding events and mortality demonstrated with Eliqus (apixaban) compared to warfarin were consistent across subgroups defined based on levels of International Normalized Ratio control in patients with nonvalvular atrial fibrillation

Butt noted that tivozanib is in several trials, including the TAURUS study, which is comparing the AVEO drug with Sutent (sunitinib, Pfizer Inc

one biosimilar version of human growth hormone (Pfizer Inc.'s Genotropin

Pfizer Inc

Active Biotech AB, of Lund, Sweden, and Ipsen SA, of Paris, said they now plan to conduct the primary progression-free survival analysis for the 10TASQ10 global Phase III trial of tasquinimod in 2014, at the same time as the first interim overall survival analysis, when more mature data are available. The product, a small molecule that binds to S100A9, is the subject of a study across 37 countries in 1,245 metastatic castrate-resistant prostate cancer patients who have not yet received

Even though the market is crowded with competitors like Nexavar, Sutent (sunitinib, Pfizer Inc.), Torisel (temsirolimus, Pfizer Inc.) and Votrient (pazopanib, GlaxoSmithKline plc), AVEO hoped to clean up by positioning tivozanib as a best-in-class option. (See BioWorld Today, Feb. 17, 2011.) Looking beyond tivozanib's July 28 PDUFA date for the advanced RCC indication, AVEO is developing the drug for other cancers

At Pfizer right now we've really cut back our R&D budget," said Margi McLoughlin, senior director of business development for Pfizer Inc

Pfizer Inc., of New York, presented results from a Phase III study investigating immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in adults 18 to 49

Inc., of Whitehouse Station, N.J., and Pfizer Inc., of New York, have entered a worldwide (except Japan) collaborative agreement for the development and commercialization of Pfizer's ertugliflozin (PF-04971729), an investigational oral sodium glucose co-transporter (SGLT2) inhibitor being evaluated for the treatment of Type II diabetes